Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2009. The document serves as a notification of transactions involving Persons Discharging Managerial Responsibility (PDMRs) in compliance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions related to executive compensation.
Transaction details include:
- Ordinary Shares: Sold at a price of £11.33 per share on February 23, 2009.
- American Depositary Shares (ADSs): Sold at a price of $32.55 per ADS on February 23, 2009.
Material Changes
The filing reports changes in shareholdings for five individuals holding Ordinary shares and one individual holding ADSs. These changes resulted from the sale of shares to meet tax liabilities following the vesting of Share Value Plan awards. No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory notification of insider trading activity.
Important Facts for Investors
- Transactions were executed on February 23, 2009, and notified on February 24, 2009.
- Sales were conducted by PDMRs specifically to satisfy tax obligations arising from Share Value Plan vesting.
- Specific individuals involved include Mr. S M Bicknell, Mr. E J Gray, Mr. D Learmouth, Mr. D S Redfern, Ms. C Thomas, and Mr. W C Louv.
- The filing does not contain financial performance data or strategic updates.